2014-2015监测年度中国B型流感病毒对神经氨酸酶抑制剂的敏感性  

Susceptibility of influenza B viruses to neuraminidase inhibitors during 2014 to 2015 in China's Mainland

作　　者：李希妍[1] 黄维娟[1] 成艳辉[1] 隗合江[1] 蓝雨[1] 谭敏菊[1] 肖宁[1] 王大燕[1] 舒跃龙[1] 

机构地区：[1]中国疾病预防控制中心病毒病预防控制所国家流感中心,卫生和计划生育委员会医学病毒和病毒病重点实验室,北京102206

出　　处：《中华微生物学和免疫学杂志》2016年第10期753-757,共5页Chinese Journal of Microbiology and Immunology

摘　　要：目的：分析2014—2015流感监测年度我国B型流感病毒对神经氨酸酶抑制剂的药物敏感性。方法选择本监测年度中国分离的1386株B型流感病毒,进行生物学耐药检测,检测病毒对奥司他韦和扎那米韦的药物敏感性。结果在检测的1386株B型流感病毒中,94株Victoria系病毒均为奥司他韦及扎那米韦的敏感株。1292株Yamagata系病毒中,有1株病毒只对奥司他韦敏感性降低,其NA基因存在I221T位点突变；有10株病毒仅对扎那米韦敏感性降低,此10株病毒中有4株病毒NA基因存在D197N氨基酸位点突变；有3株病毒对2种药物的敏感性均降低,此3株病毒的NA基因均具有D197N位点突变；另有1株病毒对奥司他韦敏感性降低,同时又对扎那米韦敏感性高度降低,其NA基因具有A245T位点突变。结论2014—2015流感监测年度我国B型流感病毒中绝大多数病毒对神经氨酸酶抑制剂敏感,临床上可继续使用此类药物对流感患者进行治疗。应持续进行耐药性监测,密切关注B型流感病毒D197N位点突变情况,及时发现耐药病毒。Objective To analyze the phenotypic characteristics of antiviral-resistant influenza B viruses circulating in China's Mainland and to analyze the susceptibility of influenza B viruses to neuraminidase inhibitors （ NAIs） . Methods Antiviral-resistant phenotyping test was performed to analyze the NAI suscep-tibility of 1 386 influenza B viruses isolated in China's Mainland from April 2014 to March 2015, including the test of susceptibility to oseltamivir and zanamivir. Results All of the 94 B-Victoria lineage viruses were sensitive to oseltamivir and zanamivir. Of all 1 292 B-Yamagata lineage viruses tested, 1 virus showed re-duced sensitivity to oseltamivir with NA gene containing I221T amino acid mutation, 10 viruses showed re-duced sensitivity to zanamivir with 4 having D197N amino acid mutation in NA gene, 3 viruses showed re-duced sensitivity to both oseltamivir and zanamivir with NA gene possessing D197N amino acid mutation and 1 virus carrying the A245T amino acid mutation in NA gene showed reduced sensitivity to oseltamivir and highly reduced sensitivity to zanamivir. Conclusion The majority of influenza B viruses circulating in main-land China during 2014 to 2015 were sensitive to NAIs, which indicated that NAIs could be used continually for clinical treatment of patients with influenza. Sustained monitoring of antiviral susceptibility of influenza B viruses should be emphasized for timely detection of antiviral resistant viruses and more attention should be paid to the D197N mutations in NA gene of influenza B viruses.

关 键 词：B型流感病毒 神经氨酸酶抑制剂 敏感性 

分 类 号：R511.7[医药卫生—内科学]